Advancing Patient Safety and Returns Security with SAP and TrueMed
AI-powered image verification can secure pharmaceutical returns without packaging or production-line changes.
Have counterfeits been infiltrated into the returns to Boehringer Ingelheim?
That was a question, Boehringer Ingelheim tried to answer by engaging into a proof of concept with two technology providers, SAP and TrueMed.
Product comes back from hospitals, wholesalers and pharmacies every day. It is processed, logged and credited. In most pharmaceutical companies, brand protection at that stage is light or non-existent. Reimbursement is paid on whatever product arrives. That makes returns one of the easiest routes for a counterfeit to re-enter the legitimate supply chain, and get paid for it.
Securing this route does not have to mean a new capital project. When image verification runs as part of the serialization process a company already operates, there is no additional infrastructure investment. No new packaging. No new hardware. No changes to the production line. The serialization data, systems and returns workflow already in place do the heavy lifting. AI adds the layer that proves the product in the box is real.
Boehringer Ingelheim decided not to wait for the industry to catch up. On October 15, it joined SAP and TrueMed for a webinar showing how it is elevating patient safety and raising the bar on returns security. Four speakers led the session:
- Jyrki Berg, CEO and Co-Founder, TrueMed
- Klaus Imig, IT Supply Chain Integrity, Boehringer Ingelheim
- Mark McGee, Executive Director, US Supply, Boehringer Ingelheim
- Dennis Keilbach, Head of Life Sciences Serialization Product Management, SAP
They covered three things: why product returns need protecting, the pilot run inside Boehringer Ingelheim’s U.S. reverse logistics operation, and what the results mean for pharmaceutical companies. Here is a recap.
Patient safety is the starting point
Boehringer Ingelheim’s motivation was clear from the start. Patient safety sits at the top of its agenda, and the company treats every link in the supply chain as part of that commitment, including the ones most companies overlook. While Boehringer Ingelheim focused on returns deemed for destruction – a counterfeit that slips back in through returns elsewhere may re-enter the supply chain. It can be resold, redistributed and eventually reach a patient, if the serialization information can be authenticated.
The threat is not standing still. Counterfeiters grow more sophisticated every year. They hunt for new revenue and for weak points in the system. The World Health Organization estimates that around 1 in 10 medical products in low- and middle-income countries is substandard or falsified. Returns are exactly the kind of weak point sophisticated actors look for.
The industry’s tools have lagged. Counterfeit identification, analysis and forensic intelligence have long been limited, slow and manual. Physical security features can be copied. A valid serial code can be duplicated onto a fake carton. Rather than accept those limits, Boehringer Ingelheim went looking for a better answer, one that would protect patients without changing how it manufactures or packages medicine.
Three companies, one closed loop
Boehringer Ingelheim led the initiative and brought in the partners to deliver it. Each one contributed a piece the others did not have.
Boehringer Ingelheim brought the vision, the products and a mature serialization operation. It already complies with the FDA’s Drug Supply Chain Security Act (DSCSA) and runs one global hub for all of its serialization processes. Its U.S. returns are handled centrally at a reverse logistics service provider. That foundation gave the pilot a single, controlled point where every returned carton passes through, and made fast integration possible.
SAP brought the backbone. SAP Advanced Track and Trace for Pharmaceuticals (ATTP) and the SAP Traceability Hub form one global hub for all of Boehringer Ingelheim’s serialization processes. They connect contract manufacturing, the internal supply chain, 3PLs, regulatory databases and reverse logistics. SAP’s Verification Router Service checks serial data under DSCSA. SAP dashboards give the business one place to see results.
“TrueMed connects to SAP Traceability Hub, so there is no new system to build. Traceability Hub was designed for flexibility. It exchanges messages in all types of formats, and our central messaging cockpit, Manage Messages, is extensible. That means a TrueMed result shows up right next to the serialization data teams already work with every day. For companies already running SAP serialization, this can be set up in a week or two.” Dennis Keilbach, Head of Life Sciences Serialization Product Management, SAP
TrueMed brought the AI. TrueMed’s platform authenticates a product from its images alone. It compares the returned carton against the genuine artwork: logo, text, colors and layout. Nothing is added to the packaging or the production line. The product image is the security feature.
Together they built a closed loop. Each stage adds evidence to the same tracking record, keyed to the product’s unique serial number (EPC).
- Capture. At the returns center, staff scan the carton’s Data Matrix code on the flap (GTIN, serial, batch, expiry) and take a top-view image of the carton artwork.
- Create the record. The SAP Traceability Hub opens a record with the EPC as the key for all results.
- Verify. The serial number is checked against the Verification Router Service.
- Analyze. TrueMed’s AI compares the carton’s artwork against the genuine reference it was trained on.
- Write the result. The verdict is written back to the same EPC record in SAP.
- Monitor. Teams review alerts and trends in SAP dashboards, with detailed results in TrueMed for deeper counterfeit analysis.
After the returns center submits the images, everything runs automatically. There is no separate system for operators to learn. The check happens inside the process Boehringer Ingelheim and SAP already run.
“What makes this work for us is that it is fully integrated with our existing serialization process. We did not change our packaging, our production lines or our returns workflow, and there was no need for further investment in new infrastructure. We added a strong layer of protection to the systems we already run.” Klaus Imig, IT Supply Chain Integrity, Boehringer Ingelheim
The live demo showed that flow end to end: returns intake, serialization validation, TrueMed AI verification and the result landing in the Boehringer Ingelheim SAP dashboard. A verified carton simply reads “TrueMed Check: PASS.”
What the pilot showed
Boehringer Ingelheim set the pilot a clear test. Could AI reliably check whether each returned product is genuine, inside a real returns operation, without changing the product? The answer was yes. The AI platform did what was promised.
Six outcomes stood out.
- Visibility in SAP. Every returned product’s status, and the reason for any failure, appears directly in the SAP dashboard.
- Stronger authentication. Image verification adds a strong authentication layer to Boehringer Ingelheim’s supply chain integrity program. No changes to the factory or the product were required.
- Infiltration identified before payment. Suspect product can be flagged before reimbursement is issued. That tightens fraud control and stops counterfeiters from being paid for returning fakes.
- Digital evidence. Every return can be photographed, creating a record of the condition it came back in.
- Forensic intelligence. Results can feed forensic systems, helping teams trace fraudulent and non-compliant cases back to their source.
- AI proven in practice. Today’s AI can be deployed now to make the supply chain safer and improve patient safety.
One finding matters more than the rest for anyone running a large portfolio. Verification can be switched on for products already in the market. No artwork update is required. Protection starts with the packaging that already exists.
Why this matters for patient safety
Serialization tells you whether a code is valid. It cannot tell you whether the box carrying that code is real. Pairing serial checks with image-based authentication answers both questions at once, for every returned unit.
That changes the economics for counterfeiters. Across the industry, returns have long been credited largely on trust. With image verification, every returned unit can be checked before credit is issued. Each fake caught is one less fake resold into the market, and one less risk to a patient.
It also changes what brand protection teams know. Returns stop being a blind spot and become a source of intelligence. Every image, result and failure reason is stored against the serial number. Patterns that were invisible become visible.
What comes next
The pilot proved the model in U.S. reverse logistics. The same approach applies anywhere product images can be captured: quality complaints, field investigations, customs checks and market surveillance. TrueMed’s platform is built to fuse those inputs into one intelligence picture for investigation and enforcement.
Boehringer Ingelheim has shown what proactive brand protection looks like. It saw an industry-wide gap early, assembled the right partners and proved a solution inside its own operations. Raising the bar did not require new packaging, new hardware or a new process. It required leadership, and the right partners connected in the right place.
Missed the session, or want to see the demo?
Contact Jyrki Berg at Jyrki.Berg@truemedinc.com.



